StockData
GoodRx Holdings, Inc. logo

GoodRx Holdings, Inc. (GDRX) stock

GDRXNasdaqServices-Computer Processing & Data PreparationFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 11/3037% below fair value
$3.36−0.11 (-3.17%)

Close on Nov 18, 2026Market cap $1.15BP/E 84.0Yield –

GoodRx operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

GoodRx's operating income for the twelve months ending Jun 30, 2026 was $74.94M, down 15.6% year over year. For fiscal 2025 it was $87.49M, up 32.9% from the year before. The highest annual figure on record is $139.68M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$87.49M+32.9%
FY2024Dec 31, 2024$65.85M–
FY2023Dec 31, 2023-$27.01M-1653.9%
FY2022Dec 31, 2022$1.74M-87.0%
FY2021Dec 31, 2021$13.41M–
FY2020Dec 31, 2020-$275.72M-297.4%
FY2019Dec 31, 2019$139.68M+80.8%
FY2018Dec 31, 2018$77.25M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$23.63M-11.9%
Q1 FY2026Mar 31, 2026$14.01M-40.1%
Q4 FY2025Dec 31, 2025$22.68M+24.8%
Q3 FY2025Sep 30, 2025$14.62M-28.4%
Q2 FY2025Jun 30, 2025$26.81M+34.9%
Q1 FY2025Mar 31, 2025$23.38M+216.8%
Q4 FY2024Dec 31, 2024$18.18M–
Q3 FY2024Sep 30, 2024$20.41M–
Q2 FY2024Jun 30, 2024$19.88M+8.6%
Q1 FY2024Mar 31, 2024$7.38M-34.7%
Q4 FY2023Dec 31, 2023-$18.29M-1152.8%
Q3 FY2023Sep 30, 2023-$38.33M–
Q2 FY2023Jun 30, 2023$18.31M–
Q1 FY2023Mar 31, 2023$11.30M-42.8%
Q4 FY2022Dec 31, 2022$1.74M-85.2%
Q3 FY2022Sep 30, 2022-$15.71M-324.5%
Q2 FY2022Jun 30, 2022-$4.05M–
Q1 FY2022Mar 31, 2022$19.76M–
Q4 FY2021Dec 31, 2021$11.76M–
Q3 FY2021Sep 30, 2021$7.00M–
Q2 FY2021Jun 30, 2021-$351.00K-100.8%
Q1 FY2021Mar 31, 2021-$5.00M-111.4%
Q4 FY2020Dec 31, 2020-$299.44M-937.2%
Q3 FY2020Sep 30, 2020-$61.69M-263.0%
Q2 FY2020Jun 30, 2020$41.74M–
Q1 FY2020Mar 31, 2020$43.67M–
Q4 FY2019Dec 31, 2019$35.77M–
Q3 FY2019Sep 30, 2019$37.84M–

More GoodRx figures

See a number that looks wrong?